Study to Characterize the Pharmacokinetics of a Single Dose of SC Abatacept 125 mg Using the BD Autoinjector or the Prefilled Syringe

Phase Ib, Multicenter, Randomized, Open-Label, Parallel-Group Study to Characterize the Pharmacokinetics of a Single Dose of Abatacept 125 mg Administered Subcutaneously Using the BD Physioject™ Autoinjector or the UltraSafe Passive Needle Guard Prefilled Syringe

The primary purpose of the protocol is to describe the pharmacokinetics of a single dose of Abatacept 125 mg in Rheumatoid Arthritis patients delivered via the autoinjector device or the approved prefilled syringe.

SC=Subcutaneous

Key Inclusion Criteria:

• Subjects ≥18 years of age
• Diagnosis of Rheumatoid Arthritis confirmed by participant's physician
• Disease activity under control

Key Exclusion Criteria:

• Change in disease-modifying antirheumatic drug (DMARD) therapy within 3 months of enrollment
• Exposure to investigational drug within 4 weeks or 5 half lives whichever is longer
• Current or prior use of Rituximab ≤6 months
• Current or prior use of the following within 4 weeks or 5 half lives whichever is longer: biologic DMARDS, Tofacitinib, Cyclophosphamide, Mycophenolate Mofetil & d-Penicillamine